Epitranscriptomics

Epitranstranscriptomics studies chemical modifications of RNA, such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C), which regulate RNA stability, splicing, and translation without altering the primary genetic sequence. According to standards set by NIST and international research consortia, these modifications represent a critical layer of gene regulation. In the context of enterprise risk management, epitranscriptomics provides a framework for assessing biological risks—such as drug-induced toxicity or cellular transformation—that traditional genomic sequencing might miss. This capability is essential for companies operating under EU AI Act or FDA pre-market approval pathways, where molecular-level indicators of product safety and efficacy are increasingly scrutinized. Understanding these epigenetic markers allows for more granular risk stratification and predictive modeling in drug development and diagnostic accuracy.

In the pharmaceutical and medical device industries, epitranstranscriptomics is applied through a three-step framework: 1) Establishing a baseline epitranscriptomic profile using LC-MS/MS or Nanopore sequencing; 2) Building predictive models correlating specific RNA modifications with phenotypic risks (e.g., oncogenic transformation or immunogenicity); 3) Integrating these markers into Quality Control (QC) protocols. For example, a European biotech firm reduced mRNA-based therapeutic batch-to-batch variability by 25% by implementing m6A-level monitoring during the manufacturing process. This application directly supports ISO 13485 compliance by providing objective molecular indicators for product-specific risk-adjusted specifications. Companies can be closely monitored for compliance with the EU AI Act's requirements for high-risk AI systems used in medical diagnostics, where RNA-based biomarkers are increasingly used as input data.

Taiwan enterprises typically face three challenges: high-cost equipment (LC-MS/MS, Nanopore), a shortage of bioinformatic experts, and evolving regulatory landscapes. To overcome these, companies should: 1) Partner with specialized CROs initially to avoid heavy CAPEX; 2. Invest in upskilling existing bioinformatics teams or collaborating with academic institutions like Academia Sinica; 3. Proactively engage with the Taiwan Food and Drug Administration (TFDA) to clarify the regulatory status of RNA-based biomarkers. A phased approach—starting with R&D-focused studies before moving to clinical-grade validation—is recommended to manage both financial and regulatory risks. The priority should be establishing a robust data-handling infrastructure that complies with the Taiwan Personal Data Protection Act (PDPA) and international standards like GDPR, especially when handling human-derived RNA samples.

Winners Consulting Services Co., Ltd. specializes in Epitranstranscriptomics for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact